Rapport Therapeutics
RAPP
About: Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Employees: 69
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
47% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 19
15% more capital invested
Capital invested by funds: $382M [Q1] → $438M (+$55.6M) [Q2]
5% more funds holding
Funds holding: 77 [Q1] → 81 (+4) [Q2]
1.08% more ownership
Funds ownership: 104.39% [Q1] → 105.47% (+1.08%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $10K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Truist Securities
Joon Lee
|
$44
|
Buy
Initiated
|
16 Sep 2025 |
|
HC Wainwright & Co.
Douglas Tsao
|
$34
|
Buy
Maintained
|
8 Sep 2025 |
|
JMP Securities
Jason Butler
|
$28
|
Market Outperform
Reiterated
|
8 Jul 2025 |
Financial journalist opinion
Based on 11 articles about RAPP published over the past 30 days
